SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann; Hannah Kleine‐Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S. Schiergens; Georg Herrler · Cell · 2020
Acceso al recurso
Entrá al contenido desde la opción principal o elegí otra fuente disponible.
Página del recurso
Cómo citar
Elegí el formato que necesitás y copiá la referencia al portapapeles.
APA 7
Hoffmann, M, Kleine‐Weber, H, Schroeder, S, Krüger, N, Herrler, T, Erichsen, S, Schiergens, T. S, & Herrler, G. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. https://doi.org/10.1016/j.cell.2020.02.052
MLA
Hoffmann, Markus, et al. "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor." 2020. https://doi.org/10.1016/j.cell.2020.02.052.
Chicago
Hoffmann, Markus, Hannah Kleine‐Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S. Schiergens, and Georg Herrler. 2020. "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.". https://doi.org/10.1016/j.cell.2020.02.052.
Harvard
Hoffmann, M. et al. 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, available at: https://doi.org/10.1016/j.cell.2020.02.052 [Accessed 29 Jun. 2026].
Detalles del recurso
Información bibliográfica útil para confirmar que se trata del material correcto.
- Título
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- Autor / colaboradores
- Markus Hoffmann; Hannah Kleine‐Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S. Schiergens; Georg Herrler
- Editorial
- Cell
- Año de publicación
- 2020
- Idioma
- en
Materias
Explorá otros recursos relacionados a partir de estas materias.